CCND1 and cancer: For example, Benitez et al., showed that expression of cyclin D1 and Cdk4 as well as cyclin D1/Cdk4 kinase activity were reduced under anticancer treatment in LNCaP, low passage (androgen-sensitive cancer line) and not in PC-3 (non-androgen sensitive cells) [40].